Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Precision Therapeutics Inc. (NASDAQ: AIPT).

Full DD Report for AIPT

You must become a subscriber to view this report.


Recent News from (NASDAQ: AIPT)

Precision Therapeutics' (AIPT) CEO Carl Schwartz on Q1 2018 Results - Earnings Call Transcript
Precision Therapeutics Inc. (AIPT) Q1 2018 Earnings Conference Call May 15, 2018, 04:30 PM ET Executives Todd Fromer - Managing Partner, KCSA Strategic Communications, IR Carl Schwartz - Chief Executive Officer Richard Gabriel - Head of External Business Development for TumorGene...
Source: SeekingAlpha
Date: May, 15 2018 20:06
Precision Therapeutics reports Q1 results
Precision Therapeutics (NASDAQ: AIPT ): Q1 EPS of -$0.15 More news on: Precision Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 15 2018 16:20
Precision Therapeutics Reports First Quarter 2018 Financial Results
MINNEAPOLIS, May 15, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today financial results for the ...
Source: GlobeNewswire
Date: May, 15 2018 16:15
Precision Therapeutics Projects Meaningful STREAMWAY System Sales in Europe in the Second Half of 2018
MINNEAPOLIS, May 10, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery and producer of the FDA-approved STREAMWAY&...
Source: GlobeNewswire
Date: May, 10 2018 08:30
Precision Therapeutics to Hold Business Update Conference Call on May 15, 2018
MINNEAPOLIS, May 08, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will repor...
Source: GlobeNewswire
Date: May, 08 2018 08:30
Precision Therapeutics, Inc. Signs Letter of Intent to Purchase Remainder of Helomics Corporation Shares
MINNEAPOLIS, April 23, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has signed an LO...
Source: GlobeNewswire
Date: April, 23 2018 08:30
Precision Therapeutics, Inc. Engages Richard Gabriel to Drive Business Development Strategy for its TumorGenesis Subsidiary
MINNEAPOLIS, April 09, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced toda...
Source: GlobeNewswire
Date: April, 09 2018 08:30
CORRECTING and REPLACING - Precision Therapeutics Releases Highlights from FY 2017 Business Update Call
In a release issued under the same headline earlier today by Precision Therapeautics (NASDAQ:AIPT), please note that the forward-looking statements paragraph was missing. The corrected release follows: MINNEAPOLIS, April 04, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:...
Source: GlobeNewswire
Date: April, 04 2018 19:00
Precision Therapeutics is the First Company to Grow Cancer Cells in the Lab That React Like Tumors Inside the Body -- CEOLIVE.TV
ORLANDO, FL, April 04, 2018 (GLOBE NEWSWIRE) -- CEOLive.TV , a news organization that highlights leading CEOs, companies, and industry experts for investors, today released  a video interview  with Dr. Carl Schwartz, CEO of  Precision Therapeutics Inc  (NASDAQ:AIPT), fo...
Source: GlobeNewswire
Date: April, 04 2018 12:16
Precision Therapeutics Releases Highlights from FY 2017 Business Update Call
MINNEAPOLIS, April 04, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, a company focused on applying artificial intelligence to personalized medicine and drug discovery, today released...
Source: GlobeNewswire
Date: April, 04 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-170.990.98020.9902640.95569,081

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-203,42635,0989.7612Cover
2018-08-171,90018,36510.3458Cover
2018-08-169,35019,98246.7921Short
2018-08-157,48858,26112.8525Cover
2018-08-1432,65955,72458.6085Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AIPT.


About Precision Therapeutics Inc. (NASDAQ: AIPT)

Logo for Precision Therapeutics Inc. (NASDAQ: AIPT)

Skyline Medical Inc. has a fully automated, patented, and FDA cleared surgical fluid disposal devices the STREAMWAY System that virtually eliminates operating room workers exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment.

 

Contact Information

 

 

Current Management

  • Carl Schwartz / CEO
  • David O. Johnson / COO
  • Bob Myers / CFO
  • Sue Radtke / Controller
  • J Melville Engle /
  • Richard Gabriel /
  • Frank Mancuso, Jr. / Director
    • Frank Mancuso, Jr., age , is a veteran of the film production industry with more than years of industry experience. He is currently the President of Boss Media, LLC, which he cofounded in . Prior to joining Boss Media, Mr. Mancuso was the President of Pictures, LLC and FGM Entertainment Inc. Mr. Mancuso also has an extensive background in healthcare and has served on the boards of multiple public companies. Mr. Mancuso has been a director of Prospect Park Capital Corp. TSX VENTURE:PPK.P , a company whose strategy is to invest in early to midstage healthcare companies. Previously, he was a director at Delcath Systems, Inc. NASDAQ: DCTH , a healthcare device company dedicated to the infusion of high dose chemotherapy to targeted areas of the body for the treatment of cancer. Mr. Mancuso obtained a Bachelor of Arts degree in business and graduated with honors from Upsala College in .
  • Tim Krochuk /
  • Thomas J. McGoldrick /
  • Andrew P. Reding /
  • Carl Schwartz /

Current Share Structure

  • Market Cap: $11,449,951 - 05/14/2018
  • Authorized: 24,000,000 - 01/29/2018
  • Issue and Outstanding: 11,804,073 - 03/19/2018

 


Recent Filings from (NASDAQ: AIPT)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 04 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 06 2018
Amendment to a previously filed 8-K
Filing Type: 8-K/AFiling Source: edgar
Filing Date: February, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 10 2018

 

 


Daily Technical Chart for (NASDAQ: AIPT)

Daily Technical Chart for (NASDAQ: AIPT)


Stay tuned for daily updates and more on (NASDAQ: AIPT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AIPT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AIPT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AIPT and does not buy, sell, or trade any shares of AIPT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/